Healthcare / BiotechnologyNasdaqGS
$438.40
-9.02 (-2.06%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $3.2B · quality 65.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$111.3B
P/E
25.5x
↑EV/EBITDA
22.1x
↑ROE
21.2%
↑Gross Margin
86.2%
↑Debt/Equity
0.11
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2008–2025 · 17 años de histórico normalizado
Revenue CAGR
+28.2%
FCF CAGR
—
FCF margin
26.6%
FCF / Net income
0.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $12.00B · net income $3.95B · FCF $3.19B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||||
| Revenue | $12.00B | $12.00B | $11.02B | $9.87B | $8.93B | $7.57B | $6.21B | $4.16B | $3.05B | $2.49B | $1.70B | $1.03B | $580.4M | $1.21B | $1.53B | $1.41B | $143.4M | $101.9M | $175.5M |
| Net Income | $3.95B | $3.95B | $-535.6M | $3.62B | $3.32B | $2.34B | $2.71B | $1.18B | $2.10B | $263.5M | $-112.1M | $-556.3M | $-738.6M | $-445.0M | $-107.0M | $29.6M | $-754.6M | $-642.2M | $-459.9M |
| EBITDA | $4.87B | $4.87B | $486.3M | $4.61B | $4.44B | $2.91B | $2.97B | $1.30B | $707.6M | $184.6M | $71.3M | $-404.5M | $-629.2M | $-561.6M | $84.9M | $148.9M | $-665.6M | $-583.9M | $-430.5M |
| EPS | 15.32 | 15.32 | -2.08 | 13.89 | 12.82 | 9.01 | 10.29 | 4.51 | 8.09 | 1.04 | -0.46 | -2.31 | -3.14 | -1.98 | -0.50 | 0.14 | -3.77 | -3.71 | -3.27 |
| Gross Margin | 86.2% | 86.2% | 86.1% | 87.2% | 87.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | 37.9% | 37.9% | -2.1% | 38.3% | 47.6% | 36.7% | 46.0% | 28.8% | 20.8% | 5.0% | 0.6% | -45.2% | -119.3% | -50.3% | 3.1% | 8.1% | -485.5% | -602.6% | -263.6% |
| Net Margin | 32.9% | 32.9% | -4.9% | 36.7% | 37.2% | 30.9% | 43.7% | 28.3% | 68.8% | 10.6% | -6.6% | -53.9% | -127.2% | -36.7% | -7.0% | 2.1% | -526.3% | -630.3% | -262.0% |
| Balance Sheet | |||||||||||||||||||
| Debt/Equity | 0.11 | 0.11 | 0.11 | 0.05 | 0.06 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 3.02 | 3.02 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||||
| Free Cash Flow | $3.19B | $3.19B | $-978.0M | $3.28B | $3.93B | $2.41B | $2.99B | $1.49B | $1.17B | $745.5M | $179.5M | $-410.7M | $-624.3M | $-112.1M | $196.7M | $109.1M | $-673.5M | $-451.1M | $-258.7M |
| Returns | |||||||||||||||||||
| ROE | 21.2% | 21.2% | -3.3% | 20.6% | 23.9% | 23.2% | 31.2% | 19.3% | 47.3% | 13.0% | -9.7% | -59.2% | -68.7% | -32.8% | -10.7% | 3.8% | -149.7% | — | — |
| Valuation | |||||||||||||||||||
| P/E | 25.51 | 25.51 | — | 29.99 | 22.64 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 22.14 | 22.14 | 210.09 | 21.48 | 14.79 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 5.93 | 5.93 | 6.40 | 6.17 | 5.40 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||||
| Revenue Growth | 8.9% | 8.9% | 11.7% | 10.5% | — | 22.1% | 49.1% | 36.6% | 22.5% | 46.2% | 64.9% | 77.9% | -52.1% | -20.6% | 8.3% | 883.9% | 40.7% | -41.9% | — |
| EPS Growth | 836.5% | 836.5% | -115.0% | 8.3% | — | -12.4% | 128.2% | -44.3% | 677.9% | 326.1% | 80.1% | 26.4% | -58.6% | -296.0% | -457.1% | 103.7% | -1.6% | -13.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
36.4%
EPS terminal req.
$38.90
Spread vs growth
800.1%
5Y implied EPS CAGR
25.2%
EPS terminal req.
$47.07
Spread vs growth
811.4%
10Y implied EPS CAGR
17.3%
EPS terminal req.
$75.81
Spread vs growth
819.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-3.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.08 → 15.32
Residual
-3.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.